197 related articles for article (PubMed ID: 29261014)
1. Selective improvement of pulmonary arterial hypertension with a dual ET
Renshall L; Arnold N; West L; Braithwaite A; Pickworth J; Walker R; Alfaidi M; Chamberlain J; Casbolt H; Thompson AAR; Holt C; Iglarz M; Francis S; Lawrie A
Pulm Circ; 2018; 8(1):2045893217752328. PubMed ID: 29261014
[TBL] [Abstract][Full Text] [Related]
2. Dual ET
Nadeau V; Potus F; Boucherat O; Paradis R; Tremblay E; Iglarz M; Paulin R; Bonnet S; Provencher S
Pulm Circ; 2018; 8(1):2045893217741429. PubMed ID: 29064353
[TBL] [Abstract][Full Text] [Related]
3. Endothelin receptor antagonist macitentan or deletion of mouse mast cell protease 4 delays lesion development in atherosclerotic mice.
Houde M; Desbiens L; Schwertani A; Pejler G; Iglarz M; D'Orléans-Juste P
Life Sci; 2016 Aug; 159():71-75. PubMed ID: 26976326
[TBL] [Abstract][Full Text] [Related]
4. Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: role of ETB-receptor expression levels.
Sauvageau S; Thorin E; Villeneuve L; Dupuis J
Pulm Pharmacol Ther; 2009 Aug; 22(4):311-7. PubMed ID: 19489130
[TBL] [Abstract][Full Text] [Related]
5. Distortion of K
Angus JA; Hughes RJA; Wright CE
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226623
[TBL] [Abstract][Full Text] [Related]
6. Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner.
Lawrie A; Hameed AG; Chamberlain J; Arnold N; Kennerley A; Hopkinson K; Pickworth J; Kiely DG; Crossman DC; Francis SE
Am J Pathol; 2011 Oct; 179(4):1693-705. PubMed ID: 21835155
[TBL] [Abstract][Full Text] [Related]
7. Macitentan: An important addition to the treatment of pulmonary arterial hypertension.
Khadka A; Singh Brashier DB; Tejus A; Sharma AK
J Pharmacol Pharmacother; 2015; 6(1):53-7. PubMed ID: 25709357
[TBL] [Abstract][Full Text] [Related]
8. Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension.
Clozel M
Am J Physiol Regul Integr Comp Physiol; 2016 Oct; 311(4):R721-R726. PubMed ID: 27534881
[TBL] [Abstract][Full Text] [Related]
9. The endothelin system in pulmonary arterial hypertension.
Galié N; Manes A; Branzi A
Cardiovasc Res; 2004 Feb; 61(2):227-37. PubMed ID: 14736539
[TBL] [Abstract][Full Text] [Related]
10. Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB Receptors.
Iglarz M; Steiner P; Wanner D; Rey M; Hess P; Clozel M
J Cardiovasc Pharmacol; 2015 Oct; 66(4):332-7. PubMed ID: 25992919
[TBL] [Abstract][Full Text] [Related]
11. Selective endothelin ETA and dual ET(A)/ET(B) receptor blockade improve endothelium-dependent vasodilatation in patients with type 2 diabetes and coronary artery disease.
Rafnsson A; Shemyakin A; Pernow J
Life Sci; 2014 Nov; 118(2):435-9. PubMed ID: 24607773
[TBL] [Abstract][Full Text] [Related]
12. Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction.
Holm P
Scand Cardiovasc J Suppl; 1997; 46():1-40. PubMed ID: 9265559
[TBL] [Abstract][Full Text] [Related]
13. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
Bedan M; Grimm D; Wehland M; Simonsen U; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
[TBL] [Abstract][Full Text] [Related]
14. Novel dual endothelin receptor antagonist macitentan reverses severe pulmonary arterial hypertension in rats.
Kunita-Takanezawa M; Abe K; Hirooka Y; Kuwabara Y; Hirano K; Oka M; Sunagawa K
J Cardiovasc Pharmacol; 2014 Nov; 64(5):473-80. PubMed ID: 25084082
[TBL] [Abstract][Full Text] [Related]
15. Selective ETA vs. dual ETA/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats.
Mirabito Colafella KM; Neves KB; Montezano AC; Garrelds IM; van Veghel R; de Vries R; Uijl E; Baelde HJ; van den Meiracker AH; Touyz RM; Danser AHJ; Versmissen J
Cardiovasc Res; 2020 Aug; 116(10):1779-1790. PubMed ID: 31593221
[TBL] [Abstract][Full Text] [Related]
16. [The new endothelin receptor antagonist macitentan: Prospects for therapy of pulmonary arterial hypertension].
Avdeev SN
Ter Arkh; 2016; 88(7):89-97. PubMed ID: 27459621
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.
Sidharta PN; Krähenbühl S; Dingemanse J
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973
[TBL] [Abstract][Full Text] [Related]
18. Endothelin B Receptor Immunodynamics in Pulmonary Arterial Hypertension.
Tabeling C; González Calera CR; Lienau J; Höppner J; Tschernig T; Kershaw O; Gutbier B; Naujoks J; Herbert J; Opitz B; Gruber AD; Hocher B; Suttorp N; Heidecke H; Burmester GR; Riemekasten G; Siegert E; Kuebler WM; Witzenrath M
Front Immunol; 2022; 13():895501. PubMed ID: 35757687
[TBL] [Abstract][Full Text] [Related]
19. Endothelin ET
Vercauteren M; Trensz F; Pasquali A; Cattaneo C; Strasser DS; Hess P; Iglarz M; Clozel M
J Pharmacol Exp Ther; 2017 May; 361(2):322-333. PubMed ID: 28223322
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
